Background: The aim of the study was to evaluate the management and outcomes of the patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a secondary hospital. Methods: A total of 699 hospitalized patients who had positive rRT-PCR for SARS-CoV-2 and/or typical findings of COVID-19 at chest computed tomography (CT) were enrolled in this study. Demographics, comorbities, initial laboratory tests on admission, treatment modalities, complications and outcomes were evaluated retrospectively. Results: The mean age was 57.0±15.6 (range:16-94 years), and male:female ratio was 1.24. 58.7% of the patients had at least one underlying comorbidity, the most common was hypertension. 72.8% of the patients had positive RT-PCR. 18.1% of the patients had lymphopenia, 35.7% hyperferritinemia, 58.3% increased lactate dehydrogenase, and 58.5% increased D-dimer. Chest CT revealed moderate and severe stage in 57.9% of the patients, and bilateral lung involvement in 78.7%. Hydroxychloroquine was given to 37.2% and favipiravir 67.1% of the patients. No significant difference was observed between treatment groups in terms of mortality (P=0.487). 5.8% of the patients were transferred to the ICU, of whom 75.6% were needed non-invasive and 36.5% invasive mechanical ventilation. The overall case fatality rate was 0.9. Conclusions: Older age, male sex, low lymphocyte count, CT findings including bilateral involvement and severe stage were significantly associated with poor prognosis and mortality.